

Link a Progetto e CV	Codice	Responsabile scientifico	Istituzione	Titolo dello studio	Budget Finanziato da Contratto (€)
<a href="http://www.aifa.gov.it/sites/default/files/2_Corrado_Barbui_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/2_Corrado_Barbui_Bando_2016.pdf</a>	AIFA-2016-0234923	Corrado Barbui	Dipartimento di neuroscienze, biomedicina e movimento dell'Università degli Studi di Verona	Assessing safety and efficacy of Vortioxetine versus SSRIs in elderly patients with depression: a pragmatic, multicenter, open-label, parallel-group, superiority, randomized trial (Version 3, 05/12/2016). VESPA study: Vortioxetine in the Elderly vs. SSRIs: a Pragmatic Assessment.	680.500,00
<a href="http://www.aifa.gov.it/sites/default/files/3_Alfredo_Berruti_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/3_Alfredo_Berruti_Bando_2016.pdf</a>	AIFA-2016-02364512	Alfredo Berruti	ASST degli Spedali Civili di Brescia	Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Adrenocortical Carcinoma with high risk of recurrence (Trial ACACIA)	378.000,00
<b>Di prossima pubblicazione</b>	AIFA-2016-02364539	Maria Luisa Bianchi	Istituto Auxologico Italiano	Glycogen Storage Disease Type I And Bone: Identification Of Risk Factors For Bone Loss And Fractures	*
<b>Di prossima pubblicazione</b>	AIFA-2016-02364594	Fabio Blandini	Fondazione Istituto Neurologico Nazionale Casimiro Mondino	Biological Markers Of Frailty In The Physiological And Pathological Aging Brain: Correlations With Pharmacological Frailty	*
<a href="http://www.aifa.gov.it/sites/default/files/6_Mario_Boccardo_o_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/6_Mario_Boccardo_o_Bando_2016.pdf</a>	AIFA-2016-02364784	Mario Boccardo	Università degli Studi di Torino	A Randomized, multicenter, open label study comparing two standard treatments, bortezomib-melphalan-prednisone (VMP) vs lenalidomide-dexamethasone (Rd) in elderly community population affected by multiple myeloma (MM)	337.040,00
<a href="http://www.aifa.gov.it/sites/default/files/7_Marco_Cattaneo_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/7_Marco_Cattaneo_Bando_2016.pdf</a>	AIFA-2016-02364723	Marco Cattaneo	Dipartimento di Scienze della Salute, Università degli Studi di Milano, Ospedale San Paolo	Pharmacokinetics And Pharmacodynamics Of Acetylsalicylic Acid In High-Risk Pregnancy	479.469,61
<a href="http://www.aifa.gov.it/sites/default/files/8_Maria_Gisella_Cavallo_Bando-2016.pdf">http://www.aifa.gov.it/sites/default/files/8_Maria_Gisella_Cavallo_Bando-2016.pdf</a>	AIFA-2016-02364864	Maria Gisella Cavallo	Sapienza Università di Roma	A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to address a gender-specific frailty. The SLOWDOWN (Sitagliptin in Diabetes for Osteoporosis in Women) study	496.389,00
<a href="http://www.aifa.gov.it/sites/default/files/9_Gianluigi_Condorelli_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/9_Gianluigi_Condorelli_Bando_2016.pdf</a>	AIFA-2016-02364544	Gianluigi Condorelli	IRCCS Istituto Clinico Humanitas	Evaluation of Cardioprotection by the use of betablocker Nebivolol in patients with breast cancer or diffuse large B cell lymphoma undergoing chemotherapy with anthracyclines: a randomized controlled trial	466.092,24
<b>Di prossima pubblicazione</b>	AIFA-2016-02364494	Alessandro Consolaro	IRCCS Giannina Gaslini	Comparison of Step-Up and step-Down therapeutic strategies in Childhood Arthritis	*

Link a Progetto e CV	Codice	Responsabile scientifico	Istituzione	Titolo dello studio	Budget Finanziato da Contratto (€)
<a href="http://www.aifa.gov.it/sites/default/files/11_Andrea_De_Censi_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/11_Andrea_De_Censi_Bando_2016.pdf</a>	AIFA-2016-02364326	Andrea De Censi	E.O Galliera	Exemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A randomized phase III Trial, expert.	1.101.108,00
<a href="http://www.aifa.gov.it/sites/default/files/12_Giovanni_De_Gaetano_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/12_Giovanni_De_Gaetano_Bando_2016.pdf</a>	AIFA-2016-02364690	Giovanni De Gaetano	Fondazione Neuromed	Polypharmacy and the Elderly: Prevalence, Clinical Impact and Epigenetic Changes in the Population-based Cohort of the Moli-sani study	1.194.050,00
<a href="http://www.aifa.gov.it/sites/default/files/13_Elisabetta_Dejana_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/13_Elisabetta_Dejana_Bando_2016.pdf</a>	AIFA-2016-02364593	Elisabetta Dejana	IFOM Fondazione Istituto FIRC di Oncologia Molecolare	A multicenter randomized clinical trial on propranolol in Familial Cerebral Cavernous Malformation	761.748,40
<b>Di prossima pubblicazione</b>	AIFA 2016-02364976	Andres J.M. Ferreri	IRCCS Ospedale San Raffaele	Randomized phase II Trial on fitness - and comorbidity - tailored treatment in elderly patients with newly diagnosed primary CNS lymphoma	*
<a href="http://www.aifa.gov.it/sites/default/files/15_Elisabetta_Ferretti_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/15_Elisabetta_Ferretti_Bando_2016.pdf</a>	AIFA-2016-02365049	Elisabetta Ferretti	Sapienza Università di Roma	Circulating microRNAs and DNA (cfDNA) as novel biomarkers for diagnostic, prognostic and therapeutic use in Medullary Thyroid Carcinoma	983.497,87
<a href="http://www.aifa.gov.it/sites/default/files/16_Roberto_Gambari_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/16_Roberto_Gambari_Bando_2016.pdf</a>	AIFA-2016-02364887	Roberto Gambari	Dipartimento di Scienze della Vita e Biotecnologie - Università di Ferrara	TREATMENT OF BETA-THALASSEMIA PATIENTS WITH RAPAMYCIN (SIROLIMUS): FROM PRE-CLINICAL RESEARCH TO A CLINICAL TRIAL	856.000,00
<a href="http://www.aifa.gov.it/sites/default/files/17_Marina_Garassino_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/17_Marina_Garassino_Bando_2016.pdf</a>	AIFA-2016-02364595	Marina Garassino	Fondazione IRCCS Istituto Nazionale dei Tumori	Improving treatment strategies in Thymic Epithelial Tumors: a TYME collaborative effort	1.552.717,00
<a href="http://www.aifa.gov.it/sites/default/files/18_Loreto_Gesualdo_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/18_Loreto_Gesualdo_Bando_2016.pdf</a>	AIFA-2016-02365060	Loreto Gesualdo	Università degli Studi di Bari Aldo Moro	Metformin versus Tolvaptan in adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD): a phase 3a, independent, multi-centre, 2 parallel arms randomized controlled trial	2.113.000,00
<b>Di prossima pubblicazione</b>	AIFA-2016-02364782	Chiara Maria Grana	Istituto Europeo di Oncologia S.r.l.	Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumours.	*

Link a Progetto e CV	Codice	Responsabile scientifico	Istituzione	Titolo dello studio	Budget Finanziato da Contratto (€)
Di prossima pubblicazione	AIFA-2016-02364631	Franco Locatelli	Ospedale Pediatrico Bambino Gesù, IRCCS	First-in-human Italian Phase I-II Trial based on adoptive Chimeric Antigen receptor (CAR)-Tcells specific for GD2 antigen in patients with high-risk neuroblastoma (HR NB)	*
<a href="http://www.aifa.gov.it/sites/default/files/21_Aurelio_Maggio_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/21_Aurelio_Maggio_Bando_2016.pdf</a>	AIFA-2016-02364612	Aurelio Maggio	Fondazione Franco e Piera Cutino Onlus	Multicentric Randomized Clinical Trial of Deferasirox-Deferiprone Sequential Therapy versus Deferasirox or Deferiprone	386.290,00
Di prossima pubblicazione	AIFA-2016-02364318	Riccardo Magistroni	IRCCS Ospedale San Raffaele	A Randomized Controlled Trial of 2-Deoxy-D-Glucose for the treatment of Autosomal Dominant Polycystic Kidney Disease	*
<a href="http://www.aifa.gov.it/sites/default/files/23_Jessica_Mandrioli_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/23_Jessica_Mandrioli_Bando_2016.pdf</a>	AIFA-2016-02364678	Jessica Mandrioli	Azienda Ospedaliero-Universitaria di Modena	Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial	990.600,00
<a href="http://www.aifa.gov.it/sites/default/files/24_Paolo_Manzonei_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/24_Paolo_Manzonei_Bando_2016.pdf</a>	AIFA-2016-02364386	Paolo Manzoni	Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino	Randomized, multi-center, open-label study on Respiratory SEquelae after RSV Bronchiolitis in PREterm babies (PRESERV)	600.00,00
<a href="http://www.aifa.gov.it/sites/default/files/25_Lucia_Margari_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/25_Lucia_Margari_Bando_2016.pdf</a>	AIFA-2016-02365052	Lucia Margari	Università degli Studi di Bari Aldo Moro (Dipartimento Scienze Mediche di Base Neuroscienze ed Organi di Senso)	Multi-centre, randomised, open label pragmatic label to compare the effectiveness and safety of interferon-beta 1a (IFN beta 1a) weekly i.m and glatiramer-acetate (GA) in paediatric patients affected by multiple sclerosis	439.950,00
<a href="http://www.aifa.gov.it/sites/default/files/26_Roberto_Massa_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/26_Roberto_Massa_Bando_2016.pdf</a>	AIFA-2016-02364987	Roberto Massa	Università degli studi di Roma Tor Vergata	EFFICACY OF METFORMIN ON MOTILITY AND STRENGTH IN MYOTONIC DYSTROPHY TYPE 1. A randomized, double blind, placebo-controlled, multicenter clinical trial.	401.600,00
<a href="http://www.aifa.gov.it/sites/default/files/27_Piero_Parchi_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/27_Piero_Parchi_Bando_2016.pdf</a>	AIFA-2016-02364982	Piero Parchi	Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Alma Mater Studiorum Università di Bologna	OXYTOCIN RESEARCH FOR BEHAVIORAL IMPAIRMENT SYMPTOMS IN DEMENTIA: Potential clinical efficacy of intranasal oxytocin in the treatment of frontotemporal dementia. A randomized, double-blind, placebo-controlled crossover trial.	173.256,15
<a href="http://www.aifa.gov.it/sites/default/files/28_Massimo_Mauri_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/28_Massimo_Mauri_Bando_2016.pdf</a>	AIFA-2016-02364852	Massimo Mauri	Fondazione IRCCS CA' GRANDA Ospedale Maggiore Policlinico	Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study. (CAT-PSY)	488.792,11
<a href="http://www.aifa.gov.it/sites/default/files/29_Giovanni_Montini_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/29_Giovanni_Montini_Bando_2016.pdf</a>	AIFA-2016-02364896	Giovanni Montini	Fondazione IRCCS CA' GRANDA Ospedale Maggiore Policlinico	A Phase 2 Open-Label Study To Evaluate The Efficacy Of Allogeneic Human Cord Blood-Derived Mesenchymal Stromal Cells In Maintaining Remission After Immunosuppressive Therapy Withdrawal In Pediatric Patients With Steroid-Dependent Nephrotic Syndrome	840.855,20
<a href="http://www.aifa.gov.it/sites/default/files/30_Eduardo_Nobile_Orazio_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/30_Eduardo_Nobile_Orazio_Bando_2016.pdf</a>	AIFA-2016-02364540	Eduardo Nobile Orazio	IRCCS Istituto Clinico Humanitas	A randomized controlled trial with Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a study based on the Italian Database of CIDP patients	697.323,27
<a href="http://www.aifa.gov.it/sites/default/files/31_Giovanni_Palladini_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/31_Giovanni_Palladini_Bando_2016.pdf</a>	AIFA-2016-02364602	Giovanni Palladini	Fondazione I.R.C.C.S. Policlinico San Matteo	A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy-TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transthyretin	647.298,00

Link a Progetto e CV	Codice	Responsabile scientifico	Istituzione	Titolo dello studio	Budget Finanziato da Contratto (€)
<a href="http://www.aifa.gov.it/sites/default/files/32_Alberto_Papi_Bando-2016.pdf">http://www.aifa.gov.it/sites/default/files/32_Alberto_Papi_Bando-2016.pdf</a>	AIFA-2016-02364957	Alberto Papi	Dipartimento di Scienze Mediche Università di Ferrara	Comparison of 1-year treatment with inhaled bronchodilators (labd) plus inhaled glucocorticosteroids (ics) versus labd without ics on re-hospitalizations and/or death in elderly patients with chronic obstructive pulmonary disease (copd) recently hospitalized because of an acute exacerbation of copd (icslife)	2.946.318,00
<a href="http://www.aifa.gov.it/sites/default/files/33_Giancarlo_Parenti_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/33_Giancarlo_Parenti_Bando_2016.pdf</a>	AIFA-2016-02364305	Giancarlo Parenti	Dipartimento di Scienze mediche traslazionali dell'Università degli Studi di Napoli Federico II	Micro-Rna As Novel Biomarkers For Lysosomal Storage Diseases	234.500,00
<b>Di prossima pubblicazione</b>	AIFA-2016-02364714	Maria Teresa Pellecchia	Università degli Studi di Salerno - Dipartimento di Medicina, Chirurgia e Odontoiatria "Scuola Medica Salernitana"	Gender-related predictors of development of fluctuations and dyskinesia in Parkinson's disease: a 2-year observational longitudinal study	*
<a href="http://www.aifa.gov.it/sites/default/files/35_Flora_Peyvandi_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/35_Flora_Peyvandi_Bando_2016.pdf</a>	AIFA-2016-02365016	Flora Peyvandi	Fondazione IRCCS CA' GRANDA Ospedale Maggiore Policlinico	Inhibitor development in previously untreated patients with severe hemophilia A, first treated with plasma-derived factor VIII and then switched to recombinant product:an international, multicenter, prospective, controlled, randomized, open label, clinical trial, SIPPET 2	630.500,00
<b>Di prossima pubblicazione</b>	AIFA-2016-02364973	Antonio Pinto	Fondazione Italiana Linfomi Onlus	A randomized, open-label, multicenter, phase III, 2-arm study comparing efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL)	*
<a href="http://www.aifa.gov.it/sites/default/files/37_Nicolo_Pipitone_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/37_Nicolo_Pipitone_Bando_2016.pdf</a>	AIFA-2016-02364869	Nicolò Pipitone	Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia	Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis	326.849,00
<a href="http://www.aifa.gov.it/sites/default/files/38_Massimo_Rambaldi_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/38_Massimo_Rambaldi_Bando_2016.pdf</a>	AIFA-2016-02364730	Alessandro Rambaldi	Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII	Phase I/II Trial of Donor Derived Cytokine Induced Killer (CIK) Cells Infusion for Relapsed Hematologic Malignancy after Hapoidentical Stem Cell Transplantation Cell Transplantation	392.150,20
<a href="http://www.aifa.gov.it/sites/default/files/39_Giovanni_Ristori_Bando-2016.pdf">http://www.aifa.gov.it/sites/default/files/39_Giovanni_Ristori_Bando-2016.pdf</a>	AIFA-2016-02365063	Giovanni Ristori	Dipartimento di neuroscienze, salute mentale e organi di senso dell'Università Sapienza di Roma	Riluzole in patients with spinocerebellar ataxia type 7: a randomized , double-blind, placebo-controlled pilot trial with a lead in phase.	275.980,00
<a href="http://www.aifa.gov.it/sites/default/files/40_Gianni_Soraru_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/40_Gianni_Soraru_Bando_2016.pdf</a>	AIFA-2016-02364843	Gianni Sorarù	Azienda Ospedaliera di Padova	A Placebo-controlled Study to Evaluate the Efficacy and Safety of Clenbuterol in Patients With Spinal and Bulbar Muscular Atrophy (SBMA).	604.726,80
<a href="http://www.aifa.gov.it/sites/default/files/41_Marina_Vivarelli_Bando_2016.pdf">http://www.aifa.gov.it/sites/default/files/41_Marina_Vivarelli_Bando_2016.pdf</a>	AIFA-2016-02364623	Marina Vivarelli	IRCCS Ospedale Pediatrico Bambino Gesù	A prospective study to assess safety and efficacy of the use of bone-marrow derived MEsenchymal stromal cells as immunomodulatory therapy for children and young adults with severe and difficult-to-treat frequently relapsing or steroid-dependent idiopathic NEPHrotic syndrome: the MESNEPH study	515.200,00

\* di prossima pubblicazione